# Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery

> **NCT00082121** · PHASE2 · COMPLETED · sponsor: **Avant Immunotherapeutics** · enrollment: 300 (—)

## Conditions studied

- Myocardial Ischemia
- Coronary Arteriosclerosis
- Aortic Valve Insufficiency
- Mitral Valve Insufficiency

## Interventions

- **DRUG:** TP10

## Key facts

- **NCT ID:** NCT00082121
- **Lead sponsor:** Avant Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 300 (—)
- **Last updated:** 2007-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082121, "Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00082121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*